Severe adverse events due to dihydropyrimidine dehydrogenase deficiency in a Japanese patient with colon cancer taking capecitabine: a case report

• Published in: International cancer conference journal 2018-10, Vol.7 (4), p.125-129
• Main Authors: Tsutsui, Mai, Yamamoto, Seiichiro, Yoshikawa, Yusuke, Nakanishi, Ryo, Takano, Kiminori, Osumi, Koji, Akatsu, Tomotaka, Yoneyama, Kimiyasu, Nakagawa, Motohito, Kanai, Toshio
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Antibiotics; Blood; Body temperature; Cancer therapies; Case Report; Case reports; Chemotherapy; Colon cancer; Colony-stimulating factor; Colorectal cancer; Colorectal carcinoma; Dehydrogenases; Diarrhea; Enzymatic activity; Enzymes; Granulocytes; Hospitals; Laparoscopy; Leukocytes; Leukocytes (granulocytic); Medicine; Medicine & Public Health; Metastases; Mucositis; Neutropenia; Oncology; Patients; Peripheral blood; Protein deficiency; Proteins; Rectum; Side effects; Surgical Oncology; Toxicity
• ISSN: 2192-3183; 2192-3183
• DOI: 10.1007/s13691-018-0334-1

Fluoropyrimidine has been commonly used not only in unresectable cases of metastatic colorectal cancer, but also in adjuvant therapy. Dihydropyrimidine dehydrogenase (DPD) is an enzyme encoded by the DPYD gene , which is responsible for the rate-limiting step in pyrimidine catabolism and breaks down more than 80% of standard doses of 5-fluorouracil (5-FU) and capecitabine, an oral prodrug of 5-FU. The lack of enzymatic activity increases the half-life of the drug, resulting in excess drug accumulation and toxicity which may lead to life-threatening side effects. There have been several published case reports about DPD deficiency in patients with colorectal cancer in Western countries. However, case reports of DPD deficiency in Japanese patients with colorectal cancer are rare because measuring DPD activity is not covered by public medical insurance in Japan, and it is not examined in our daily clinical practice currently. Therefore, we think that it is important to accumulate such case reports for further understanding. This report describes the case of a Japanese patient with colon cancer who experienced severe side effects while taking capecitabine, due to DPD deficiency. A 68-year-old man with ascending colon cancer underwent curative laparoscopic right hemicolectomy. Because final pathologic staging was Stage IIIa, standard adjuvant chemotherapy with capecitabine (3600 mg/body/day, days 1–14, every 3 weeks) was started on postoperative day 50. After 2 weeks, he started to experience Grade 3 diarrhea and was admitted to the hospital on postoperative day 66. On day 70, the patient had Grade 4 febrile neutropenia. Antibiotics and granulocyte-colony-stimulating factor were administered until his blood tests recovered to the normal degree. After 1 week of diarrhea, antidiarrheal agents were administered, and the patient gradually recovered. During the occurrence of diarrhea, specimen cultures were negative for infection. He was discharged on day 21 of the hospital stay. DPD deficiency was suspected, and 2 weeks later the DPD activity of the peripheral blood mononucleocytes was examined. The result was 10.3 U/mg protein which was remarkedly low (reference range 22.6–183.6 U/mg protein), and DPD deficiency was diagnosed. We always must consider the possibility of DPD deficiency in patients who experience severe side effects while taking capecitabine.